<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393377</url>
  </required_header>
  <id_info>
    <org_study_id>AGE-ZT</org_study_id>
    <nct_id>NCT03393377</nct_id>
  </id_info>
  <brief_title>Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination</brief_title>
  <acronym>AGE-ZT</acronym>
  <official_title>Preventive Arterial Wall Phenotype in Subjects at Moderate Cardiovascular Risk Induced by Very Low-dose Fluvastatin/Valsartan Combination: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to test whether short-term treatment with a very low-dose combination
      of fluvastatin and valsartan could induce improvement of endothelial function, arterial
      stiffness, vascular inflammation, oxidative stress and expression of protective genes in
      subjects with moderate cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The largest population that suffers from cardiovascular events are subjects at moderate
      cardiovascular risk. However, no effective and safe preventive treatment is available for
      this population. This study aimed to investigate whether their arterial wall phenotype could
      be turned to a preventive direction by low-dose fluvastatin/valsartan combination
      (low-flu/val).

      Twenty males at moderate cardiovascular risk (as classified by SCORE) were blindly randomised
      into the intervention group (n=10, low-flu/val: 10 mg/20mg) or control group (n=10, placebo).
      At inclusion and after 30 days of treatment, brachial flow-mediated dilatation (FMD), beta
      stiffness coefficient, carotid pulse wave velocity (c-PWV), carotid-femoral PWV, reactive
      hyperaemia index, high-sensitivity C-reactive protein (hs-CRP), interleukin 6, vascular cell
      adhesion molecule 1, total antioxidant status and expression of several protective genes
      (SIRT1, mTOR, NF-κB1, NFE2L2, PRKAA1) were followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brachial flow-mediated dilatation (FMD)</measure>
    <time_frame>30 days</time_frame>
    <description>FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reactive hyperaemia index (RHI)</measure>
    <time_frame>30 days</time_frame>
    <description>RHI measured by Endopat device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>beta stiffness coefficient</measure>
    <time_frame>30 days</time_frame>
    <description>assessed by ultrasound employing e-Tracking on right common carotid artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid pulse wave velocity (c-PWV)</measure>
    <time_frame>30 days</time_frame>
    <description>assessed by ultrasound employing e-Tracking on right common carotid artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid-femoral PWV (cf-PWV)</measure>
    <time_frame>30 days</time_frame>
    <description>cf-PWV measured by Sphygmocor device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>30 days</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 6 (IL-6)</measure>
    <time_frame>30 days</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vascular cell adhesion molecule 1 (VCAM1)</measure>
    <time_frame>30 days</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total antioxidant status (TAS)</measure>
    <time_frame>30 days</time_frame>
    <description>marker of oxidative stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene SIRT1</measure>
    <time_frame>30 days</time_frame>
    <description>Hs01009006_m1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene mTOR</measure>
    <time_frame>30 days</time_frame>
    <description>Hs00234522_m1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene NF-kB1</measure>
    <time_frame>30 days</time_frame>
    <description>Hs00765730_m1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene Nrf2/NFE2L2</measure>
    <time_frame>30 days</time_frame>
    <description>Hs00975961_g1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene AMPK/PRKAA1</measure>
    <time_frame>30 days</time_frame>
    <description>Hs01562315_m1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>brachial flow-mediated dilatation (FMD)</measure>
    <time_frame>10 weeks after treatment completion</time_frame>
    <description>FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactive hyperaemia index (RHI)</measure>
    <time_frame>10 weeks after treatment completion</time_frame>
    <description>RHI measured by Endopat device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta stiffness coefficient</measure>
    <time_frame>10 weeks after treatment completion</time_frame>
    <description>assessed by ultrasound employing e-Tracking on right common carotid artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid pulse wave velocity (c-PWV)</measure>
    <time_frame>10 weeks after treatment completion</time_frame>
    <description>assessed by ultrasound employing e-Tracking on right common carotid artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid-femoral PWV (cf-PWV)</measure>
    <time_frame>10 weeks after treatment completion</time_frame>
    <description>cf-PWV measured by Sphygmocor device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received placebo for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin 10 mg and valsartan 20 mg</intervention_name>
    <arm_group_label>intervention group</arm_group_label>
    <other_name>low-flu/val</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate cardiovascular risk according to Systematic Coronary Risk Estimation (SCORE)
             risk charts of the European Society of Cardiology

          -  males

          -  aged between 40 and 55 years

        Exclusion Criteria:

          -  diabetes mellitus

          -  manifest peripheral artery disease or carotid artery disease

          -  acute infection

          -  chronic diseases

          -  present therapy with fluvastatin and/or valsartan
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.</citation>
    <PMID>27222591</PMID>
  </reference>
  <reference>
    <citation>Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2015 Nov 13;4(11). pii: e002270. doi: 10.1161/JAHA.115.002270. Review.</citation>
    <PMID>26567372</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. Review.</citation>
    <PMID>20338492</PMID>
  </reference>
  <reference>
    <citation>Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol. 2017 Apr 18;69(15):1952-1967. doi: 10.1016/j.jacc.2017.01.064. Review.</citation>
    <PMID>28408026</PMID>
  </reference>
  <reference>
    <citation>Lunder M, Janić M, Jug B, Sabovič M. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med. 2012 Apr;23(3):261-6. doi: 10.1016/j.ejim.2011.11.011. Epub 2011 Dec 12.</citation>
    <PMID>22385885</PMID>
  </reference>
  <reference>
    <citation>Boncelj Svetek M, Eržen B, Kanc K, Šabovič M. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. J Diabetes Complications. 2017 Mar;31(3):544-550. doi: 10.1016/j.jdiacomp.2016.12.002. Epub 2016 Dec 16.</citation>
    <PMID>28012835</PMID>
  </reference>
  <reference>
    <citation>Janić M, Lunder M, Prezelj M, Šabovič M. A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males. J Cardiopulm Rehabil Prev. 2014 May-Jun;34(3):208-12. doi: 10.1097/HCR.0000000000000027.</citation>
    <PMID>24263076</PMID>
  </reference>
  <reference>
    <citation>Sosnowska B, Mazidi M, Penson P, Gluba-Brzózka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017 Oct;265:275-282. doi: 10.1016/j.atherosclerosis.2017.08.027. Epub 2017 Aug 26. Review.</citation>
    <PMID>28870631</PMID>
  </reference>
  <reference>
    <citation>Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2.</citation>
    <PMID>27040132</PMID>
  </reference>
  <reference>
    <citation>Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2779-85. doi: 10.1016/j.jacc.2014.04.009. Epub 2014 May 7.</citation>
    <PMID>24814489</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Martina Turk Veselič</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>arterial stiffness</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>fluvastatin</keyword>
  <keyword>valsartan</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>SIRT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

